Topical dexamethasone-cyclodextrin microparticle eye drops for diabetic macular edema

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 11, 2011, Pages 7944-7948

  Tanito, Masaki ^a   Hara, Katsunori ^a   Takai, Yasuyuki ^a   Matsuoka, Yotaro ^a   Nishimura, Nobuhiro ^a   Jansook, Phatsawee ^b   Loftsson, Thorsteinn ^b   Stefánsson, Einar ^b   Ohira, Akihiro ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b UNIVERSITY OF ICELAND   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLODEXTRIN; DEXAMETHASONE; BETA CYCLODEXTRIN DERIVATIVE; DEXAMETHASONE BETA CYCLODEXTRIN; DEXAMETHASONE-BETA-CYCLODEXTRIN; DRUG DERIVATIVE; EYE DROPS; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIABETIC MACULAR EDEMA; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MALE; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA MACULA LUTEA; SPECTRAL DOMAIN OPTICAL COHERENT TOMOGRAPHY; VISUAL ACUITY; DIABETIC RETINOPATHY; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA MACULA EDEMA; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; AGED; AGED, 80 AND OVER; BETA-CYCLODEXTRINS; DEXAMETHASONE; DIABETIC RETINOPATHY; FEMALE; GLUCOCORTICOIDS; HUMANS; INTRAOCULAR PRESSURE; MACULA LUTEA; MACULAR EDEMA; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PILOT PROJECTS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84555187190     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-8178     Document Type: Article

References (20)

1. Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2010;117:2146-2151.
2. Bandello F, Iacono P, Battaglia Parodi M. Treatment options for diffuse diabetic macular edema. Eur J Ophthalmol. 2010;21:45-50.
3. Steijns D, Duijvesz D, Breedijk MA, van der Heijden GJ. Steroid injection in addition to macular laser grid photocoagulation in diabetic macular oedema: a systematic review. Acta Ophthalmol. 2010;88:389-393.
4. Rensch F, Spandau UH, Wickenhauser A, Jonas JB. Diffuse diabetic macular oedema treated with intravitreal bevacizumab or triamcinolone acetonide. Acta Ophthalmol. 2010;88:e36-e37.
5. Boyer DS, Faber D, Gupta S, et al. Dexamethasone intravitreal implant for diabetic macular edema in vitrectomized patients. Retina. 2011;31:915-923.
6. Ginka T, inventor; Mpex Pharmaceuticals, Inc., assignee. Bacterial efflux pump inhibitors and methods of treating bacterial infections. US patent 7,893,020 B2. February 22, 2011.
7. Jansook P, Ritthidej GC, Ueda H, Stefansson E, Loftsson T. yCD/ HPyCD mixtures as solubilizer: solid-state characterization and sample dexamethasone eye drop suspension. J Pharm Pharm Sci. 2010;13:336-350.
8. Loftsson T, Hreinsdottir D, Stefansson E. Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops. J Pharm Pharmacol. 2007;59: 629-635.
9. Loftsson T, Sigurdsson HH, Konradsdottir F, Gisladottir S, Jansook P, Stefansson E. Topical drug delivery to the posterior segment of the eye: anatomical and physiological considerations. Pharmazie. 2008;63:171-179.
10. Sigurdsson HH, Konraethsdottir F, Loftsson T, Stefansson E. Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye. Acta Ophthalmol Scand. 2007;85:598-602.
11. Kristinsson JK, Fridriksdottir H, Thorisdottir S, Sigurdardottir AM, Stefansson E, Loftsson T. Dexamethasone-cyclodextrin-polymer co-complexes in aqueous eye drops: aqueous humor pharmacokinetics in humans. Invest Ophthalmol Vis Sci. 1996;37:1199-1203.
12. Saari KM, Nelimarkka L, Ahola V, Loftsson T, Stefansson E. Comparison of topical 0.7% dexamethasone-cyclodextrin with 0.1% dexamethasone sodium phosphate for postcataract inflammation. Graefes Arch Clin Exp Ophthalmol. 2006;244:620-626.
13. Jansook P, Stefansson E, Thorsteinsdottir M, et al. Cyclodextrin solubilization of carbonic anhydrase inhibitor drugs: formulation of dorzolamide eye drop microparticle suspension. Eur J Pharm Biopharm. 2010;76:208-214.
14. Campochiaro PA, Shah SM, Hafiz G, et al. Topical mecamylamine for diabetic macular edema. Am J Ophthalmol. 2010;149:839-851, e831.
15. Genead MA, Fishman GA. Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with retinitis pigmentosa and usher syndrome. Arch Ophthalmol. 2010;128:1146-1150.
16. Nakano S, Yamamoto T, Kirii E, Abe S, Yamashita H. Steroid eye drop treatment (difluprednate ophthalmic emulsion) is effective in reducing refractory diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2010;248:805-810.
17. Gisladottir S, Loftsson T, Stefansson E. Diffusion characteristics of vitreous humour and saline solution follow the Stokes Einstein equation. Graefes Arch Clin Exp Ophthalmol. 2009;247:1677-1684.
18. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins: basic science and product development. J Pharm Pharmacol. 2010;62:1607-1621.
19. Munro IC, Newberne PM, Young VR, Bar A. Safety assessment of gamma-cyclodextrin. Regul Toxicol Pharmacol. 2004;39(suppl 1): S3-S13.
20. Gudmundsdottir E, Stefansson E, Bjarnadottir G, et al. Methazolamide 1% in cyclodextrin solution lowers IOP in human ocular hypertension. Invest Ophthalmol Vis Sci. 2000;41:3552-3554.